Finally, our results suggest that patients diagnosed with malignant ER+ breast cancer may benefit from combination therapy consisting of IL1R1 and PDGFRβ blockers to enhance the effectiveness of endocrine therapies such as Tam. Here, PDGFRB is linked to breast carcinoma.